{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:17:04Z","timestamp":1785500224577,"version":"3.56.0"},"reference-count":25,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":1896,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background: Riedel thyroiditis (RT) is a rare form of thyroiditis; thus, data about the disease course and treatment options are limited. Therefore, we aimed to assess the clinical, serological, radiological, and histopathological features, as well as short- and long-term follow-up of RT patients under glucocorticoid (GC) and tamoxifen citrate (TMX). Parameters related to IgG4-related diseases (IgG4-RD) were also investigated. Methods: Eight patients with RT diagnosed between 2000 and 2019 were enrolled. Data were collected in a retrospective and prospective manner. The diagnosis was confirmed with histopathological features in all patients. Results of the treatment with GCs on short- to mid-term, followed by TMX in the long term, were evaluated. Results: The mean age at diagnosis was 40.5 \u00b1 6.8 years; female predominance was observed (F\/M:7\/1). Parameters related to IgG4-RD, like increase in IgG4 serum levels, total plasmablast counts, and IgG4+ plasmablasts, were negative in most of our patients in both active and inactive states of the disease. Likewise, an increased ratio of IgG4\/IgG-positive plasma cells &amp;gt;40% could only be observed in 2 cases. GCs followed by TMX were given to the patients with an over-all median follow-up time of 67 (8\u2013216) months. All the patients considerably improved clinically and had a reduction in the size of the mass lesion on GCs, followed by TMX therapy. None of the patients had a recurrence under TMX therapy for a median period of 18.5 (7\u201396) months. Conclusion: Even though RT is suggested to be a member of IgG4-RD, serologic or histological evidence of IgG4 elevation or positivity is only useful for diagnosis and follow-up of RT. The diagnosis should be based on clinical and radiological evidence and confirmed by histopathology. GCs are effective for initial treatment, and TMX is a successful and safe therapeutic option for long-term maintenance therapy.<\/jats:p>","DOI":"10.1159\/000512017","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T17:03:32Z","timestamp":1607447012000},"page":"248-256","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":6,"title":["Long-Term Outcomes of Tamoxifen Citrate Therapy and Histo- and Immunopathological Properties in Riedel Thyroiditis"],"prefix":"10.1530","volume":"10","author":[{"given":"Asena","family":"G\u00f6k\u00e7ay Canpolat","sequence":"first","affiliation":[{"name":"1Department of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Cinel","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serpil","family":"Dizbay Sak","sequence":"additional","affiliation":[{"name":"2Department of Pathology, School of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u015f\u0131lay","family":"Ta\u015fkald\u0131ran","sequence":"additional","affiliation":[{"name":"3Department of Endocrinology and Metabolism, Ankara Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5066-6335","authenticated-orcid":false,"given":"Hakan","family":"Korkmaz","sequence":"additional","affiliation":[{"name":"4Department of Endocrinology and Metabolism, School of Medicine, S\u00fcleyman Demirel University, Isparta, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"Demir","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhan","family":"Ersoy","sequence":"additional","affiliation":[{"name":"5Department of Endocrinology and Metabolism, School of Medicine, Y\u0131ld\u0131r\u0131m Beyaz\u0131t University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sel\u00e7uk","family":"Da\u011fdelen","sequence":"additional","affiliation":[{"name":"6Department of Endocrinology and Metabolism, School of Medicine, Hacettepe University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Berker","sequence":"additional","affiliation":[{"name":"7Department of Endocrinology and Metabolism, Ankara City Hospital, University of Health Sciences, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Dalva","sequence":"additional","affiliation":[{"name":"8Department of Haematology, School of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adile Beg\u00fcm","family":"Bah\u00e7ecio\u011flu Mutlu","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0867-6393","authenticated-orcid":false,"given":"Murat Faik","family":"Erdo\u011fan","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology and Metabolism, School of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"2026070711513622600_ref1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/TCRM.S99985","article-title":"IgG4-related disease: current challenges and future prospects","volume":"12","author":"Lang","year":"2016","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"2026070711513622600_ref2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1507\/endocrj.EJ15-0175","article-title":"Clinicopathological features of Riedel\u2019s thyroiditis associated with IgG4-related disease in Japan","volume":"62","author":"Takeshima","year":"2015","journal-title":"Endocr J"},{"issue":"7","key":"2026070711513622600_ref3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1089\/thy.2010.0453","article-title":"Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience 1976\u20132008","volume":"21","author":"Fatourechi","year":"2011","journal-title":"Thyroid"},{"issue":"10","key":"2026070711513622600_ref4","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1210\/jc.2011-0617","article-title":"Clinical review: Riedel\u2019s thyroiditis: a clinical review","volume":"96","author":"Hennessey","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711513622600_ref5","doi-asserted-by":"crossref","first-page":"709264","DOI":"10.1155\/2011\/709264","article-title":"Variable clinical presentations of Riedel\u2019s thyroiditis: report of two cases","volume":"2011","author":"Zakeri","year":"2011","journal-title":"Case Rep Med"},{"issue":"9","key":"2026070711513622600_ref6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"issue":"1","key":"2026070711513622600_ref7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12020-018-1526-3","article-title":"Riedel\u2019s thyroiditis: clinical presentation, treatment and outcomes","volume":"60","author":"Falhammar","year":"2018","journal-title":"Endocrine"},{"issue":"10","key":"2026070711513622600_ref8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.autrev.2015.06.003","article-title":"The changing faces of IgG4-related disease: clinical manifestations and pathogenesis","volume":"14","author":"Islam","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2026070711513622600_ref9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/annrheumdis-2014-205233","article-title":"Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations","volume":"74","author":"Wallace","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2026070711513622600_ref10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s12020-009-9168-0","article-title":"A case of Riedel\u2019s thyroiditis with pleural and pericardial effusions","volume":"35","author":"Erdogan","year":"2009","journal-title":"Endocrine"},{"issue":"1","key":"2026070711513622600_ref11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2013-204907","article-title":"The diagnostic utility of serum IgG4 concentrations in IgG4-related disease","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2026070711513622600_ref12","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/MPA.0000000000000118","article-title":"Serum immunoglobulin G4 level is a poor predictor of immunoglobulin G4-related disease","volume":"43","author":"Ngwa","year":"2014","journal-title":"Pancreas"},{"issue":"5","key":"2026070711513622600_ref13","doi-asserted-by":"crossref","first-page":"R175","DOI":"10.1530\/EJE-18-1024","article-title":"Diagnosis of endocrine disease: IgG4-related thyroid autoimmune disease","volume":"180","author":"Rotondi","year":"2019  1","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026070711513622600_ref14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF03347818","article-title":"Fibrous invasive (Riedel\u2019s) thyroiditis with critical response to steroid treatment","volume":"18","author":"Bagnasco","year":"1995","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"2026070711513622600_ref15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/acr.20215","article-title":"Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum","volume":"62","author":"Dahlgren","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"4","key":"2026070711513622600_ref16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1507\/endocrj.EJ11-0309","article-title":"IgG4-related disease of the thyroid glands","volume":"59","author":"Kakudo","year":"2012","journal-title":"Endocr J"},{"issue":"6","key":"2026070711513622600_ref17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0039-6060(96)80045-6","article-title":"Riedel\u2019s thyroiditis: treatment with tamoxifen","volume":"120","author":"Few","year":"1996","journal-title":"Surgery"},{"issue":"866","key":"2026070711513622600_ref18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/pgmj.73.866.817","article-title":"Corticosteroid therapy in Riedel\u2019s thyroiditis","volume":"73","author":"Vaidya","year":"1997","journal-title":"Postgrad Med J"},{"issue":"10","key":"2026070711513622600_ref19","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1097\/00005537-200410000-00015","article-title":"Tamoxifen therapy for Riedel\u2019s thyroiditis","volume":"114","author":"Pritchyk","year":"2004","journal-title":"Laryngoscope"},{"issue":"7","key":"2026070711513622600_ref20","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"2026070711513622600_ref21","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1210\/jc.2012-4050","article-title":"Novel use of rituximab in a case of Riedel\u2019s thyroiditis refractory to glucocorticoids and tamoxifen","volume":"98","author":"Soh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026070711513622600_ref22","first-page":"17-0132","article-title":"Rituximab: a novel treatment for refractory Riedel\u2019s thyroiditis","volume":"2018","author":"Hunt","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"6","key":"2026070711513622600_ref23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4158\/EP.10.6.483","article-title":"A case of Riedel\u2019s thyroiditis treated with tamoxifen: another successful outcome","volume":"10","author":"Jung","year":"2004 \u2013","journal-title":"Endocr Pract"},{"issue":"1","key":"2026070711513622600_ref24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/thy.2009.0324","article-title":"Combined mycophenolate mofetil and prednisone therapy in tamoxifen- and prednisone-resistant Reidel\u2019s thyroiditis","volume":"20","author":"Levy","year":"2010","journal-title":"Thyroid"},{"issue":"6","key":"2026070711513622600_ref25","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1046\/j.1365-2125.1998.00733.x","article-title":"Tamoxifen and risk of idiopathic venous thromboembolism","volume":"45","author":"Meier","year":"1998","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/512017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/10\/3\/248\/21756\/etj512017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/10\/3\/248\/21756\/etj512017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:27:25Z","timestamp":1783441645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/10\/3\/248\/2745\/Long-Term-Outcomes-of-Tamoxifen-Citrate-Therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000512017","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,8]]}}}